Agenus (AGEN) vs Vanda Pharmaceuticals (VNDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Agenus (AGEN) has outperformed Vanda Pharmaceuticals (VNDA) over the past year, gaining 80.8% versus a loss of 16.1%. Over five years, VNDA leads with a -75.2% price change compared with -92.8% for AGEN. Agenus is the larger company by market cap ($346.4 million vs $276.3 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGEN | VNDA |
|---|---|---|
| Share price | $7.67 | $4.57 |
| Market cap | $346.39M | $276.31M |
| 1-day change | +1.72% | +0.88% |
| YTD return | +140.13% | -48.19% |
| 1-year return | +80.82% | -16.15% |
| 5-year return | -92.77% | -75.18% |
| P/E ratio (TTM) | 3.03 | — |
| Forward P/E | — | 22.85 |
| EPS (TTM) | $2.53 | $-4.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.31 | $9.94 |
| 52-week low | $2.71 | $4.27 |
| Distance from 52-week high | -25.61% | -54.02% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +243.29% | +157.11% |
| Average volume | 4.26M | 974.13K |
| Shares outstanding | 45.16M | 60.46M |
| Employees | 81 | 533 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AGEN has outperformed VNDA by 97.0 percentage points over the past year.
About Agenus
AGEN stock →Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About Vanda Pharmaceuticals
VNDA stock →Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.
Health Care · Biotechnology: Pharmaceutical Preparations · 533 employees
AGEN vs VNDA FAQ
Which is bigger, Agenus or Vanda Pharmaceuticals?
Agenus (AGEN) is larger, with a market capitalization of $346.39M compared with $276.31M for Vanda Pharmaceuticals (VNDA).
Which stock has performed better over the past year, AGEN or VNDA?
AGEN returned +80.82% over the past 12 months, compared with -16.15% for VNDA (price return, excluding dividends). Past performance does not predict future results.
Are Agenus and Vanda Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Agenus and Biotechnology: Pharmaceutical Preparations for Vanda Pharmaceuticals.